Business Wire

CA-PSMF

Share
Patient Safety Movement Foundation Announces Winners of 2021 Humanitarian and Lewis Blackman Awards

The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient deaths by 2030, announced the winners of its 2021 Humanitarian and Lewis Blackman awards at its 8th annual World Patient Safety, Science & Technology Summit (WPSSTS). President Bill Clinton, the 42nd President of the United States, was recognized with the Joe Kiani Humanitarian award, Javier Davila received the Beau Biden Humanitarian award and Jannicke Mellin-Olson was honored with the Steven Moreau Humanitarian award. The 2nd annual Lewis Blackman award was presented to Ingrid Bonilla.

“Achieving our mission of zero preventable patient deaths by 2030 relies on individuals coming together to create change,” said Michael Ramsay, MD, CEO of Patient Safety Movement Foundation. “We are proud to recognize all four of this year’s winners for their individual efforts, leadership and commitment to improving patient safety globally.”

The Humanitarian Awards recognize leaders who have made significant progress in the last year eliminating or raising awareness of preventable patient deaths. This year, recipients were honored across three categories – the Joe Kiani award, Beau Biden award and Steven Moreau award. The Joe Kiani award was named after the founder of the Patient Safety Movement Foundation and recognizes individuals who are committed to the foundation’s mission. The Beau Biden award was created in 2018 to honor Beau Biden, former attorney general of Delaware, member of the Army National Guard and late son of President Joe Biden, for his devotion to public service and the safety of others, especially children. The Steven Moreau award is presented annually to a hospital administrator who possesses a zeal for improving patient safety at their hospital. This year’s recipients included:

  • President Bill Clinton , 42nd President of the United States, has been a long-standing supporter of patient safety. During his time in office, he was committed to expanding access to affordable, quality health care for all Americans. He received the first-ever Joe Kiani award for his continued support of the Patient Safety Movement Foundation and its goal to reach zero preventable medical deaths by 2030.
  • Javier Davila , PSMF ambassador in Mexico, former medical director at the Mexican Social Security Institute and head of medical education, research and health public policy, was recognized with the Beau Biden award for his passion for public service and improving patient safety for others. Since joining PSMF, he has focused on promoting the culture of safety in Mexico and has helped build affiliations with many prestigious public and private hospitals, as well as establish relationships with numerous organizations to help further the mission.
  • Jannicke Mellin-Olson , MD, DPH, has been a longtime patient safety advocate. Her passion for patient safety started during her residency at Trondheim University Hospital in Norway, where she worked on a number of patient safety initiatives. She received the Steven Moreau award for her continued efforts to spread the mission to stakeholders across Europe, as well as in her current clinical post at Baerum Hospital in Oslo, Norway.

The Lewis Blackman Leadership Award was established in 2020 to recognize active students or residents pursuing a career in healthcare who demonstrate exemplary leadership skills in patient safety that contribute to PSMF’s vision of eliminating preventable medical harm. It was designed in honor of Lewis Blackman, who died on November 6, 2000 at the age of 15, as a result of preventable medical harm in a healthcare setting with a poor culture of safety and inadequate training. Before his death, he was an outstanding student and his mother, Helen Haskell, has become an advocate for improving patient safety, especially through education.

  • Ingrid Bonilla , fourth year medical student at Medical University of South Carolina, has demonstrated an early commitment and passion for improving patient safety. During her time in medical school, she has worked with noted patient safety champions in South Carolina on new criteria to prevent central line infections, collected data on COVID-19 to determine how it presents itself in children and how they should be treated and has also focused on improving communication between patients, families and providers.

The Patient Safety Movement Foundation launched the Humanitarian Awards in 2013 to recognize individuals whose work helps advance patient safety and the Lewis Blackman Award was created in 2019. To learn more about the awards and past winners, visit: https://patient.sm/LewisBlackman .

The full WPSSTS event is available to watch on demand for $20 through May 9, 2022 at: http://patient.sm/summit2022 or free after May 9 at: http://patient.sm/summitYT .

About the Patient Safety Movement Foundation: The Patient Safety Movement Foundation (PSMF), a global non-profit organization founded in 2012, is celebrating 10 years of bringing awareness and creating action to eliminate preventable medical errors. Some estimates predict that one in 12 patients are impacted by a preventable medical error, but that number could be even higher as there is no central database tracking these figures in most countries, including the U.S. Over the last decade, there had been major strides to improve patient safety, but the COVID-19 pandemic stressed the system and it proved not to be resilient and took a step backwards. PSMF has a vision to eliminate preventable patient harm and death across the globe by 2030 – and that starts with raising awareness of this critical issue. It unites patients, advocates, health workers, medical technology companies, government, employers and private payers in support of this cause. From its evidence-based best practice solutions (Actionable Patient Safety Solutions™) and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/patientsafetymovement/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye